Elimination of APIs in Pharmaceutical Wastewater by UV Oxidation

Rubrik: Technik

(Treffer aus pharmind, Nr. 07, Seite 893 (2022))

Sörensen M | Weckenmann J | Zegenhagen F

Elimination of APIs in Pharmaceutical Wastewater by UV Oxidation / 17 Years of Field Experience · Sörensen M, Weckenmann J, Zegenhagen F · enviolet GmbH, Karlsruhe
The pharmaceutical and chemical industries manufacture and formulate medications based on pharmaceutically active substances. Even today, there are no clear legal regulations regarding the emission of these substances into the environment, but many manufacturers of these substances and user products have established their own targets for the reduction of these emissions into the environment, even before national governments have established or implemented corresponding regulations. In most cases, the self-imposed aims of the pharmaceutical manufacturers’ treatment of factory wastewater are very challenging since they are based on the Predicted No-Effect Concentration (PNEC) in the environment. Once this treated wastewater is further ...

Elimination of APIs by UV Oxidation in Wastewater from CIP-Rinsing at a Multiple API-Formulation Facility Using Advanced Oxidation Process

Rubrik: Originale

(Treffer aus pharmind, Nr. 06, Seite 830 (2019))

Sörensen M | Weckenmann J | Zegehagen F | Miller-Reichling T | Schaffer U | Waldeck U | Marani E | Incledion M

Elimination of APIs by UV Oxidation in Wastewater from CIP-Rinsing at a Multiple API-Formulation Facility Using Advanced Oxidation Process / Sörensen et al. • Elimination of APIs · Sörensen M, Weckenmann J, Zegehagen F, Miller-Reichling T, Schaffer U, Waldeck U, Marani E, Incledion M · ¹enviolet GmbH, Karlsruhe und Catalent Germany Eberbach GmbH, Eberbach und Catalent U.K. Swindon Zydis Ltd., Swindon, U und nited und K und ingdom
The pharmaceutical facility in Eberbach, Germany, is a large softgel development and manufacturing facility with a capacity of 12.8 billion capsules per year. The system handles highly potent hormonal and cytotoxic compounds from multiple formulations from 9 different production lines, comprising up to 177 different APIs, as well as their in-house Research and Development department [ 1 ]. Since many active pharmacological ingredients can be harmful to humans and the aquatic environment, even at very low levels, proper technology has to be applied in order fulfill all current regulations and standards (e.g., biodegradability of at least 60 %). Formerly, wastewater resulting from ...

Wastewater Treatment by UV-Oxidation at Oril API Manufacturing Site

Rubrik: Praxis

(Treffer aus pharmind, Nr. 04, Seite 569 (2018))

Sörensen M | Laperdrix E | Michelet I | Zegenhagen F | Menard S | Weckenmann J

Wastewater Treatment by UV-Oxidation at Oril API Manufacturing Site / Sörensen et al. • Wastewater Treatment by UV-Oxidation · Sörensen M, Laperdrix E, Michelet I, Zegenhagen F, Menard S, Weckenmann J · ¹Enviolet, Karlsruhe und Oril Industrie, a Servier Company, Bolbec, France und MPC, Lyon und , France
Oril Industrie is a manufacturer of various API, situated near Le Havre within a nature reserve. Oril is part of Servier Laboratories SA, which is the leading independent French pharmaceutical company and the second largest French pharmaceutical company worldwide [ 1 ]. Due to the special hydrogeological location of Oril within an environmentally protected area, it is subject to very low legal limits for several substances used in the manufacturing process, in particular Morpholine (MOR). Since MOR is an amine it is likely to turn into undesirable Nitroso-Morpholine (NMOR) in the station treatment plant. Oril has two manufacturing sites within ...